u133 plus 2.0 microarray (Thermo Fisher)
Thermo Fisher is a verified supplier 
Thermo Fisher manufactures this product 
90
Structured Review
Thermo Fisher
u133 plus 2.0 microarray
U133 Plus 2.0 Microarray, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u133+microarray/pm39788641-379-22-18
Average 90 stars, based on 1 article reviews
U133 Plus 2.0 Microarray, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u133+microarray/pm39788641-379-22-18
Average 90 stars, based on 1 article reviews
u133 plus 2.0 microarray - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Microarray:Article Title: Single-Cell Heterogeneity of EGFR Pathway Is Linked to Unique Signatures of Drug Response and Malignancy in Patient Derived Glioblastoma Stem Cells. Article Snippet: Because of the lack of gene name overlap from the Article Title: Technological advances and computational approaches for alternative splicing analysis in single cells Article Snippet: Developed for single-cell short-read RNA-sequencing , Custom pipeline , Article Title: Technological advances and computational approaches for alternative splicing analysis in single cells Article Snippet: , Custom pipeline , Article Title: Single-Cell Heterogeneity of EGFR Pathway Is Linked to Unique Signatures of Drug Response and Malignancy in Patient Derived Glioblastoma Stem Cells. Article Snippet: All rights reserved. gene name overlap from the Article Title: CRISPRs in the human genome are differentially expressed between malignant and normal adjacent to tumor tissue. Article Snippet: Related to our findings that sncRNAs were originating from our hCRISPRs and could be used to distinguish malignant from normal adjacent to Article Title: Distinct pathway activities are associated with prognosis and response to bortezomib-containing treatment in MCL1-M based molecular subtypes of multiple myeloma. Article Snippet: 1 Department of Biology, Beijing Key Laboratory of Gene Resource and Molecular Development, School of Life Sciences, Key Laboratory of Cell Proliferation and Regulation Biology, School of Life Sciences, Ministry of Education, Beijing Normal University, Beijing, China 2 Clinical Research Center, The Affiliated Hospital of Guizhou Medical University, Guiyang, China 3 Department of Hematology, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China 4 College of Life Sciences, Sichuan Normal University, Chengdu, China 5 Department of Pathology, Capital Medical University Sanbo Brain Hospital, Beijing, China 6 Institute of Biomedical Sciences, Henan Academy of Sciences, Zhengzhou, China 7 Department of Physiology, University of Sindh, Jamshoro, Pakistan 8 Department of Hematology, Changzhou Second People’s Hospital of Nanjing Medical University, Changzhou, China Abstract Multiple myeloma (MM) is the second most prevalent hematological malignancy and remains incurable with remarkable heterogeneity in prognosis and treatment response across the patients.. Clinical diagnosis and the existing molecular classification systems are inadequate for predicting treatment responses.. Based on the convergence between plasma cell development and MM pathogenesis, we identified a gene co-expression module centered on the plasma cell survival regulator MCL1 (MCL1 module, MCL1-M) in the transcriptomes of pre-treated MM, which enabled stratification of MM patients into MCL1-M high and MCL1-M low molecular subtypes with subtype-specific prognosis and response to bortezomib-containing treatment. Article Title: Population pharmacokinetic analysis of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in patients and healthy volunteers Article Snippet: The genotyping was performed with the Article Title: Population pharmacokinetic analysis of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in patients and healthy volunteers. Article Snippet: The genotyping was performed with the Polymerase Chain Reaction:Article Title: Single-Cell Heterogeneity of EGFR Pathway Is Linked to Unique Signatures of Drug Response and Malignancy in Patient Derived Glioblastoma Stem Cells. Article Snippet: Because of the lack of gene name overlap from the Article Title: Technological advances and computational approaches for alternative splicing analysis in single cells Article Snippet: Developed for single-cell short-read RNA-sequencing , Custom pipeline , Article Title: Technological advances and computational approaches for alternative splicing analysis in single cells Article Snippet: , Custom pipeline , Article Title: Single-Cell Heterogeneity of EGFR Pathway Is Linked to Unique Signatures of Drug Response and Malignancy in Patient Derived Glioblastoma Stem Cells. Article Snippet: All rights reserved. gene name overlap from the Article Title: CRISPRs in the human genome are differentially expressed between malignant and normal adjacent to tumor tissue. Article Snippet: Related to our findings that sncRNAs were originating from our hCRISPRs and could be used to distinguish malignant from normal adjacent to Article Title: Distinct pathway activities are associated with prognosis and response to bortezomib-containing treatment in MCL1-M based molecular subtypes of multiple myeloma. Article Snippet: 1 Department of Biology, Beijing Key Laboratory of Gene Resource and Molecular Development, School of Life Sciences, Key Laboratory of Cell Proliferation and Regulation Biology, School of Life Sciences, Ministry of Education, Beijing Normal University, Beijing, China 2 Clinical Research Center, The Affiliated Hospital of Guizhou Medical University, Guiyang, China 3 Department of Hematology, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China 4 College of Life Sciences, Sichuan Normal University, Chengdu, China 5 Department of Pathology, Capital Medical University Sanbo Brain Hospital, Beijing, China 6 Institute of Biomedical Sciences, Henan Academy of Sciences, Zhengzhou, China 7 Department of Physiology, University of Sindh, Jamshoro, Pakistan 8 Department of Hematology, Changzhou Second People’s Hospital of Nanjing Medical University, Changzhou, China Abstract Multiple myeloma (MM) is the second most prevalent hematological malignancy and remains incurable with remarkable heterogeneity in prognosis and treatment response across the patients.. Clinical diagnosis and the existing molecular classification systems are inadequate for predicting treatment responses.. Based on the convergence between plasma cell development and MM pathogenesis, we identified a gene co-expression module centered on the plasma cell survival regulator MCL1 (MCL1 module, MCL1-M) in the transcriptomes of pre-treated MM, which enabled stratification of MM patients into MCL1-M high and MCL1-M low molecular subtypes with subtype-specific prognosis and response to bortezomib-containing treatment. Article Title: Population pharmacokinetic analysis of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in patients and healthy volunteers Article Snippet: The genotyping was performed with the Article Title: Population pharmacokinetic analysis of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in patients and healthy volunteers. Article Snippet: The genotyping was performed with the |
![Fam170a is located in the nucleus of spermatids at steps 9–13 and has a low level of mRNA in human sperm from individuals with teratozoospermia. ( A , B ) Immunofluorescence staining displayed the localization and distribution of Fam170a protein in mouse and human seminiferous tubules, respectively. Roman numerals indicate the spermatogenic stages of the tubules in WT testicular sections. S: spermatid. The specific stages of mouse tubules were determined according to published criteria [ , ]. ( C ) Schematic summary of Fam170a protein localization during spermiogenesis. ( D ) Three different microarrays captured Fam170a gene transcription levels in sperm samples from normal and teratozoospermia men. The original data source is marked at the top of the histogram. GDS2695 ( https://www.ncbi.nlm.nih.gov/geoprofiles/?term=GDS2695±FAM170A ), GDS2696 ( https://www.ncbi.nlm.nih.gov/geoprofiles/?term=GDS2696+FAM170A ), and <t>GDS2697</t> ( https://www.ncbi.nlm.nih.gov/geoprofiles/?term=GDS2697+FAM170A ); ** P < .01, * P < .005. The data are displayed as mean ± SEM. A t -test was performed, and false discovery rate (FDR) P -values were shown. ( E ) The relative Fam170a mRNA abundance in sperm samples from normal ( n = 4) and teratozoospermia ( n = 3) men after qRT-PCR analysis. The control data are displayed as mean ± SEM.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0970/pmc11760970/pmc11760970__gkaf023fig1.jpg)